Antihypertensive medications and risk of diabetes mellitus

Current Opinion in Nephrology and Hypertension

Volumn 16, Issue 3, 2007, Pages 256-260

  Barzilay, Joshua I ^a,d   Cutler, Jeffrey A ^b   Davis, Barry R ^c  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^c UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^d NONE   (United States)

Author keywords

Angiotensin receptor blocker; Angiotensin converting enzyme inhibitor; Elevated glucose; Hypertension; Thiazide diuretic

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLUCOSE; LISINOPRIL; RAMIPRIL; RESERPINE; THIAZIDE DIURETIC AGENT;

ANTIHYPERTENSIVE THERAPY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG MECHANISM; GENETIC RISK; GLUCOSE BLOOD LEVEL; HEART FAILURE; HIGH RISK PATIENT; HUMAN; HYPERGLYCEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; STROKE;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; HUMANS; HYPERGLYCEMIA; HYPERTENSION; RISK ASSESSMENT; RISK FACTORS; SODIUM CHLORIDE SYMPORTER INHIBITORS;

EID: 34247251252     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNH.0b013e328057dea2     Document Type: Review

References (27)

1. Scheen AJ. Prevention of type 2 diabetes mellitus through inhibition of the renin-angiotensin system. Drugs 2004; 4:2537-2565.
2. Padwal R, Laupacis A. Antihypertensive therapy and incidence of type 2 diabetes: a systemic review. Diabetes Care 2004; 24:247-253.
3. Pepine CJ, Sooper-Delhof RM. Cardiovascular therapies and risk for development of diabetes. J Am Coll Cardiol 2004; 44:509-512.
4. Mason JM, Dickinson HO, Nicolson DJ, et al. The diabetogenic potential of thiazide-type diuretic and beta-blocker combinations in patients with hypertension. J Hypertens 2005; 23:1777-1781.
5. Elliott WJ. Differential effects of antihypertensive drugs on new-onset diabetes? Curr Hypertens Rep 2005; 7:249-256.
6. Asfaha S, Padwal R. Antihypertensive drugs and incidence of type 2 diabetes: evidence and implications for clinical practice. Curr Hypertens Rep 2005; 7:314-322.
7. Taylor EN, Hu FB, Curhan GC. Antihypertensive medications and the risk of incident type 2 diabetes. Diabetes Care 2006; 29:1065-1070.
8. Mancia G, Grassi G, Zanchetti A. New-onset diabetes and antihypertensive drugs. J Hypertens 2006; 24:3-10.
9. Aksnes TA, Kjeldsen SE, Manchia G. The effect of antihypertensive agents on new-onset diabetes mellitus: time to amend the guidelines? Am J Cardiovasc Drugs 2006; 6:139-147.
10. Dunder K, Lind L, Zethelius B, et al. Increase in blood glucose concentration during antihypertensive treatment as a predictor of myocardial infarction: population based cohort study. BMJ 2003; 326:681-686.
11. Petrie JR, McDougall C, Al-Mamari A, et al. Controversies from observational data: dangers for evidence-based prescribing. http://bmj. bmjjournals.com/ cgi/eletters/326/7391/681. [Accessed 7 January 2007]
12. Verdechia P, Reboldi G, Angeli F, et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 2004; 43:963-969.
13. Verdechia P, Angeli F, Reboldi GP, Gattobigio R. New-onset diabetes in treated hypertensive patients. Curr Hypertens Rep 2005; 7:174-179.
14. Barzilay JI, Davis BR, Cutler JA, et al. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to three different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2006; 166:2191-2201. An analysis of the ALLHAT study showing that even though diuretics increase fasting glucose levels and the risk of diabetes mellitus they do not impact the risk of CVD.
15. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989; 321:406-412.
16. Rowe JW, Tobin JD, Rosa RM, Andres R. Effect of experimental potassium deficiency on glucose and insulin metabolism. Metabolism 1980; 29:498-502.
17. Kostis JB, Wilson AC, Freudenberger RS, et al. Long-term effect of diureticbased therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol 2005; 95:29-35.
18. Whelton PK, Barzilay J, Cushman WC, et al. Clinical outcomes in ALLHAT antihypertensive trial participants with type 2 diabetes, impaired fasting glucose, and normoglycemia. Arch Intern Med 2005; 165:1401-1409.
19. Zillich AJ, Garg J, Sanjib B, et al. Thiazide diuretics, potassium, and the development of diabetes: a quantitative review. Hypertension 2006; 48:219-224. A review and synthesis of the impact of low potassium levels in association with diuretic use on the risk of glucose disorders.
20. Cutler JA. Thiazide-associated glucose abnormalities: prognosis, etiology, and prevention: is potassium balance the key? Hypertension 2006; 48:198-200. An analysis of how low serum potassium levels lead to elevated glucose levels.
21. Gillespie EL, White CM, Kardas M, et al. The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes. Diabetes Care 2005; 28:2261-2266.
22. Gerstein HC, Yusuf S, Bosch J, et al. DREAM (Diabetes Reduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006; 368:1096-1105.
23. DREAM Trial Investigators. Effect of ramipril on the incidence of diabetes. N Engl J Med 2006; 355:1551-1562. A trial demonstrating that ACE inhibitor use does not result in lower glucose levels compared with placebo over a 3-year follow up period.
24. Suissa S, Hutchinson T, Brophy JM, Kezouh A. ACE-inhibitor use and the long-term risk of renal failure in diabetes. Kidney Int 2006; 69:913-919. A study demonstrating that ACE inhibitor use may not be associated with amelioration of diabetic kidney disease compared with thiazide use.
25. Rahman M, Pressel S, Davis BR, ALLHAT Collaborative Research Group. Renal outcomes in high-risk hypertensive patients randomized to angiotensinconverting enzyme inhibitor or calcium channel blocker vs. diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2005; 165:936-946.
26. Placha G, Canani LH, Warram JH, Krolewski AS. Evidence for different susceptibility genes for proteinuria and ESRD in type 2 diabetes. Adv Chr Kid Dis 2005; 12:155-169.
27. Retnakaran R, Cull CA, Thorne KI, et al. Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74. Diabetes 2006; 55:1832-1839.